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N4-octadecyl-1-b-D-arabinofuranosylcytosine, NOAC (Schott et
al, 1994) is a good candidate for cancer therapy with potential
advantages compared to the related drug 1-b-D-arabinofuranosyl-
cytosine (ara-C) and to other lipophilic ara-C derivatives. To
overcome the disadvantage of rapid deamination of ara-C to the
biologically inactive metabolite 1-b-D-arabinofuranosyluracil
(ara-U), a large number of chemical modifications of ara-C were
made in the past. We synthesized lipophilic ara-C derivatives with
C16–C22 N4-alkyl side chains of which NOAC (C18) has the highest
activity in murine leukaemias and solid tumour xenograft models
(Schwendener et al, 1995). Due to the lipophilic property of
NOAC, the drug has to be incorporated in liposomes to obtain a
formulation that can be used for intravenous applications. The
pharmacological properties of the alkyl-ara-C-derivatives are
different from ara-C regarding cellular uptake, formation of ara-C-
5¢-triphosphate and induction of apoptosis (Horber et al, 1995a,
1995b, 1995c). An important finding was, that NOAC is not
tightly anchored to the liposomal lipid bilayer and thus is readily
distributed in the blood mainly into erythrocyte membranes and
lipoproteins (Koller-Lucae et al, 1997). It is known that uni-
lamellar liposomes aggregate with low density lipoproteins (LDL)
and allow the transfer of incorporated drugs from the liposomes to
LDL. Similar to the transfer of liposomal phospholipid-ara-C
conjugates to LDL as described by MacCoss et al (1983), we also
observed a strong affinity of NOAC for lipoproteins. The incuba-
tion of liposomal NOAC with human serum resulted in binding to
lipoproteins of 36% to LDL and 21% to high density lipoproteins
(HDL) (Koller-Lucae et al, 1997). Thus, liposomes provide an
ideal formulation for NOAC to assure the transfer of the drug to
lipoproteins, especially LDL.
Similar results were reported by Wasan and co-workers (1997)
for liposomal nystatin who found an increased distribution into
lipoproteins compared to free drug. The natural affinity of NOAC
for LDL provides an interesting rationale for the specific delivery
of the drug to tumours. Growing and dividing cells require
cholesterol for membrane synthesis which is delivered by LDL
(Goldstein et al, 1983). This accounts also for cancer cells where
an increased LDL uptake in tumours with high metastatic potential
and aggressive or undifferentiated character was found (Firestone,
1994). The elevated number of LDL receptors expressed on
tumour cells has been exploited for the delivery of lipophilic
drugs. Allison et al (1994) described the tumour targetting of
photosensitizers using LDL as drug carriers and van Berkel et al
(1996) used a lipid emulsion mimicking lipoprotein particles
loaded with a lipophilic antiviral drug for increased liver uptake.
Compared to normal blood cells, the LDL receptors of
lymphoma and leukaemia cells are up-regulated leading to an
increased uptake of LDL (Yen et al, 1994). For our investigation
we used the Daudi Burkitt lymphoma cell line, whose LDL
binding and uptake properties were characterized by Yen et al
(1995). For this in vitro model system we incorporated NOAC
into LDL and investigated the uptake mechanisms, cytotoxic
activity and cellular distribution of NOAC-LDL in comparison to
liposomal NOAC.
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SummaryLow density lipoprotein (LDL) receptor-mediated uptake and cytotoxic effects of N4-octadecyl-1-b-D-arabinofuranosylcytosine
(NOAC) were studied in Daudi lymphoma cells. NOAC was either incorporated into LDL or liposomes to compare specific and unspecific
uptake mechanisms. Binding of LDL to Daudi cells was not altered after NOAC incorporation (KD 60nM). Binding of liposomal NOAC was not
saturable with increasing concentrations. Specific binding of NOAC-LDL to Daudi cells was five times higher than to human lymphocytes. LDL
receptor binding could be blocked and up- or down-regulated. Co-incubation with colchicine reduced NOAC-LDL uptake by 36%. These
results suggested that NOAC-LDL is taken up via the LDL receptor pathway. In an in vitro cytotoxicity test, the IC50 of NOAC-LDL was about
160mM, whereas with liposomal NOAC the IC50 was 40mM. Blocking the LDL receptors with empty LDL protected 50% of the cells from NOAC
cytotoxicity. The cellular distribution of NOAC-LDL or NOAC-liposomes differed only in the membrane and nuclei fraction with 13% and 6%
respectively. Although it is more convenient to prepare NOAC-liposomes as compared to the loading of LDL particles with the drug, the
receptor-mediated uptake of NOAC-LDL provides an interesting rationale for the specific delivery of the drug to tumours that express elevated
numbers of LDL receptors.
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MATERIALS AND METHODS
Chemicals
NOAC was synthesized as described before (Schott et al, 1994)
and obtained from Spagomed AG (Burgdorf, Switzerland).
Soy phosphatidylcholine (SPC) was obtained from L Meyer
(Hamburg, Germany). Cholesterol (Fluka AG, Buchs,
Switzerland) was recrystalized from methanol. A stock solution of
the fluorescent probe DiI (1,1¢-dioctadecyl-3,3,3¢,3¢-tetramethyl-
indocarbocyanine perchlorate, Molecular Probes, Leiden, The
Netherlands) was prepared by dissolving 1 mg in 1 ml ethanol for
the labelling of liposomal preparations and 2.5 mg in 1 ml
dimethyl sulphoxide (DMSO) for LDL. DL-a-Tocopherol, all
buffer salts and other chemicals used were of analytical grade and
obtained from Merck (Darmstadt, Germany) or Fluka. Soluene
350 and Ultima Gold scintillation cocktail were from Packard
Instruments (Groningen, The Netherlands). NOAC was tritium
labelled (0.370 GBq mmol–1 [5-3H]-NOAC) by Amersham
(Amersham, UK). Ara-C (1-b-D-arabinofuranosylcytosine) was
dissolved in saline containing 0.01% EDTA (pH 7.4;
saline–EDTA) to 10 mM stock solution.
Culture of Daudi cells and isolation of lymphocytes
The human Burkitt lymphoma cell line, Daudi was obtained from
Dr K Melief (The Netherlands Cancer Institute, Amsterdam, The
Netherlands). The cells were grown in RPMI-1640 medium
(Gibco, Paisley, UK) supplemented with 10% heat-inactivated
fetal calf serum (FCS; Gibco), 100 units ml–1 penicillin-strepto-
mycin (Gibco) and 2 mML -glutamine (Gibco) in a humidified 5%
carbon dioxide atmosphere. Cells were subcultured three times a
week at a split ratio of 1:3 to maintain a density of 0.5–2.0 ´ 106
cells ml–1. Lymphocytes were isolated from fresh human blood
(106 ml–1 blood) which was drawn directly into Vacutainer®
CPT™ cell preparation tubes (Becton Dickinson, Basel,
Switzerland). The tubes were centrifuged (30 min, 1800 g) and the
fraction containing the lymphocytes suspended in 15 ml medium
supplemented with 10% FCS, centrifuged (10 min,
300  g) and cultured in the same medium over night. On the next
day the cells were transferred to new culture flasks to remove
monocytes. The homogeneity of the lymphocyte population was
analysed in a flow cytometer (Coulter Epics Elite, Miami, FL,
USA) by staining the cells with fluorescein isothiocyanate (FITC)-
conjugated anti-CD45 and PE-conjugated anti-CD14 antibodies
(Coulter), yielding lymphocyte populations of >92%. For the up-
or down-regulation of the LDL receptors the Daudi cells or
lymphocytes were either cultured for 48 h in serum-free medium
(RPMI-1640, penicillin–streptomycin 100 units ml–1, L-glutamine
2m M) supplemented with 10% human lipoprotein-deficient serum
(LPDS, Sigma, Buchs, Switzerland) or by replacement of LPDS
with 10% FCS supplemented with additional human LDL at a
final concentration of 440 nM LDL.
Preparation of liposomes
Small (100 nm) unilamellar liposomes were prepared in
saline–EDTA by sequential filter extrusion as described before
(Koller-Lucae et al, 1997). Liposome size and homogeneity was
determined by laser light scattering (Submicron Particle Sizer
Model 370, Nicomp, Santa Barbara, CA, USA). The basic
composition of the liposomes used was 100 mM SPC, 20 mM
cholesterol, 0.9 mMD L -a-tocopherol, and 1 mM NOAC, which
was trace labelled with [5-3H]-NOAC. Liposomes carrying an
average of 100–120 molecules NOAC, as calculated from the lipo-
some diameter and the NOAC concentration, were obtained. For
the cytotoxicity experiments liposomes with the same lipid
composition were used but NOAC was added at 20 mM (1500
molecules NOAC per liposome). For the flow cytometry experi-
ments liposomes with the same lipid composition, 1 mM DiI and
180 mM sodium cholate were prepared by dialysis against
saline–EDTA as described by Rubas et al (1986). DiI concentra-
tion was determined with a Spectrofluorometer SFM 23 (Kontron,
Zurich, Switzerland) after solubilization of an aliquot of liposomes
(20 ml) with 2 ml sodium cholate (0.05%), yielding an average of
80 DiI probes per liposome. For control experiments liposomes
without drug or DiI were processed accordingly. All liposomes
were sterile filtrated (0.2 mm, Schleicher & Schuell, Feldbach,
Switzerland) stored at 4°C and used within 2 weeks.
Isolation and loading of LDL with DiI or 3H-NOAC
LDL was obtained from fresh human plasma by sequential
flotation ultracentrifugation (Viallard et al, 1990). Isolated LDL
fractions were run on Sephadex G-25 columns (16 ´ 60 mm,
Pharmacia, Uppsala, Sweden) for buffer exchange. In order to
prevent oxidation of apolipoprotein B100, all media contained
0.01% EDTA. The apolipoprotein B100 content of the LDL prepa-
rations was measured with a Bio-Rad protein assay (Bio-Rad,
Glattbrugg, Switzerland) using albumin as standard. LDL
labelling with DiI was performed as described by Morrison et al
(1994). DiI concentration was determined fluorometrically as
described for DiI-liposomes yielding an average of 100 DiI mole-
cules per LDL. DiI-labelled LDL (DiI-LDL) is still functional in
binding to the LDL receptor (Stephan and Yurachek, 1993). The
LDL particles were loaded with NOAC as described above for
DiI-LDL by incubating 1 mg protein (0.12 ml LDL) with 0.2 mg
NOAC (in 0.6 ml DMSO), trace labelled with [5-3H]-NOAC and
named 3H-NOAC-LDL. This resulted in 40–160 molecules NOAC
per LDL which represents an incorporation rate of 20–80%. For
the cellular distribution experiment the incorporation of NOAC
was 30 molecules NOAC per LDL because the 3H-NOAC concen-
tration was increased. The purity of the LDL preparations was
assessed on agarose gels as described before (Koller-Lucae et al,
1997). All LDL preparations were sterile filtrated (0.45 mm,
Schleicher & Schuell) stored at 4°C and used within 3 weeks. The
molarity of the LDL preparations was calculated from the protein
concentrations taking into account that the protein content of an
LDL particle is 20% of the mass and the molecular mass of LDL is
2500 kDa.
Binding and association of LDL or liposomes to Daudi
cells or lymphocytes
After culturing the cells in medium with 10% FCS, 10% LPDS
or 10% FCS containing 440 nM LDL they were washed once with
serum-free medium (10 min, 800 g). After culture in LPDS for 48
h the cell viability was judged by trypan blue exclusion resulting
in >95% viability for Daudi cells and >90% for lymphocytes
respectively. Incubations were performed with 5 ´ 106 cells ml–1 in
serum-free medium. For incubations at 4°C the cells were adjusted
to temperature for 15 min, before adding liposomes or LDL. Time1544 SKM Koller-Lucae et al
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(0.25–24 h) with 144 nM LDL or liposomes and concentration-
dependent incubations were performed with
3H-NOAC-LDL or 3H-NOAC-liposomes (7–280 nM) for 2 h on
an overhead shaker (Heidolph, Kelheim, Germany) at 4°C. Each
LDL particle and liposome carried an average of 100–120 mole-
cules NOAC.
For binding studies the cells were pre-incubated with
saline–EDTA, native LDL or liposomes (250 nM) at 4 or 37°C for
1 h as described above. Then 10 nM 3H-NOAC-LDL (60 NOAC
molecules per LDL particle) or 3H-NOAC-liposomes (130 NOAC
molecules per liposome) were added and the incubation continued
for 2 h. In some experiments colchicine (1.7 mg ml–1) was added
to the incubations at 37°C to prevent non-specific uptake by fluid-
phase pinocytosis (Swanson et al, 1987). The samples were placed
on ice after incubation and washed twice with ice-cold phosphate-
buffered saline containing 0.1% bovine serum albumin
(PBS–BSA, 10 min, 280 g, 4°C). Supernatant and wash buffers
were analysed directly, whereas cell pellets were lysed with 0.2 ml
potassium hydroxide (0.2 M) before scintillation counting in a
Tri-Carb™ Liquid Scintillation Analyzer (Packard Instruments,
Groningen, The Netherlands). All incubations were performed in
triplicate. Results were calculated as LDL particles or liposomes
bound per cell and binding characteristics were determined by
fitting the data with one-site binding hyperbolas.
Flow cytometry
Time (0.25–4 h with 32 nM LDL or liposomes) and concentration
(8–140 nM LDL or liposomes, 2 h) dependent incubations were
performed at 4°C with 2.5 ´ 105 cells and DiI-LDL or DiI-lipo-
somes, as described above. The cell pellet was suspended in 1 ml
PBS–BSA containing 4% formaldehyde. Flow cytometric analysis
was performed with an Epics Elite Analyzer (Coulter). DiI-
binding or uptake was expressed as mean intensity of fluorescence
(MIF) per cell. The experiments were performed in triplicate.
Cytotoxicity test
Daudi cells were cultured in medium with 10% FCS. Before
plating the cells they were washed once in serum-deficient
medium. Incubations were performed in flat-bottom 96-well test
plates (Techno Plastic Products, Trasadingen, Switzerland) with
0.25 ´ 106 cells ml–1. NOAC was used at different concentrations
ranging from 12.5 to 200 mM. NOAC-LDL (0.13–4 mM LDL),
NOAC-liposomes (0.01–0.13 mM liposomes), NOAC dissolved in
ethanol (0.13–2 ml ethanol) and ara-C dissolved in saline–EDTA
(0.13–2 ml buffer) as well as the carriers without drug were added
to the cells. To investigate if excess LDL can block NOAC-LDL
activity, the cells were pre-incubated for 25 min with 0.4 and
1.2 mM LDL or the same volume of saline–EDTA. Then 0.6 mM
NOAC-LDL corresponding to 100 mM NOAC was added.
Incubations were performed at 37°C in a humidified 5% carbon
dioxide atmosphere for 24 h. Cell viability of untreated control
was 95% as determined by trypan blue exclusion. Then 0.01 ml
WST-1 reagent (Boehringer Mannheim, Rotkreuz, Switzerland)
was added and the plates were kept in the incubator for 2 h before
measuring the absorption on a MRX microplate reader (Dynex
Technologies, Chantilly, VA, USA). Results were calculated as per
cent of surviving cells by comparison with untreated cells. The
50% inhibitory NOAC concentration (IC50) of the different incuba-
tions was determined. To compare the effect of serum, the same
concentration-dependent incubations were performed with
medium containing 5% FCS. All experiments were done in
triplicate.
Cellular distribution of 3H-NOAC-LDL and 3H-NOAC-
liposomes
The experiments were performed as described by Horber (1995b).
Incubation was performed in 6-well plates (Techno Plastic) with
107 cells ml–1 either with 40 ml 3H-NOAC-LDL resulting in 2 mM
NOAC (70 nM LDL with 30 molecules NOAC per LDL) or
3H-NOAC-liposomes resulting in 200 mM NOAC (3 mM liposomes
with 70 molecules NOAC per liposome). Samples were collected
after 3 h and total radioactivity in the cell pellet was determined.
The cells were lysed by nitrogen gas cavitation and centrifuged to
obtain cell fractions. The drug concentration in each fraction was
determined by scintillation counting. All experiments were
performed in triplicate.
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Figure 1 Time-dependent binding to Daudi cells (A) with 144 nM 3H-NOAC-
LDL (100 NOAC molecules per LDL), 32 nM DiI-LDL (100 DiI probes per
LDL) or 144 nM 3H-NOAC-liposomes (100 NOAC molecules per liposome).
(B) Concentration-dependent binding of 3H-NOAC-LDL, DiI-LDL or 3H-
liposomes for 2 h. Binding of LDL particles or liposomes was calculated per
cell. DiI-LDL binding was determined by flow cytometry and the results
calculated as the mean intensity of fluorescence per cell (MIF). Incubations
were performed at 4°C. The results represent means of three experiments.
Data were fitted with one-site binding hyperbolas resulting in correlation
coefficients of r = 0.948 for NOAC-LDL (A), of r = 0.869 for NOAC-liposomes
(A), of r = 0.934 for NOAC-LDL (B) and r = 0.879 for DiI-LDL (B).
Concentration dependent binding of NOAC-liposomes was fitted by linear
regression with r = 0.986 (B)RESULTS
Time- and concentration-dependent binding of NOAC
Binding studies were carried out at 4°C in order to minimize inter-
nalization processes. Incubation of Daudi cells with 3H-NOAC-
LDL (144 nM LDL) during 0.25–24 h (Figure 1A) showed that
after 2 h saturation of binding was reached. Incubation with
different 3H-NOAC-LDL concentrations (Figure 1B) for 2 h
resulted in a high binding affinity to the LDL receptors with a KD
of 60 nM, a value which was also reported by Yen et al (1995) for
LDL binding to Daudi cells. Maximal binding for time or concen-
tration-dependent experiments was 600 000 LDL particles per cell.
Incubations with DiI-LDL (Figure 1B) resulted in a similar KD of
44 nM. Time-dependent incubations with DiI-LDL (Figure 1A,
closed circles) were not performed long enough to calculate satu-
ration but data correlate with 3H-NOAC-LDL binding.
3H-NOAC-liposome binding was investigated under the same
conditions. Binding was complete after 40 min with 144 nM lipo-
somes resulting in 100 000 liposomes per cell. However, with
increasing concentrations of 3H-NOAC-liposomes no saturation
was reached, resulting in a slight linear increase of binding up to
280 nM (Figure 1B). Incubations with DiI-liposomes also showed
maximal binding after 32 min and no saturation with increasing
DiI-liposome concentrations (data not shown).
Binding of NOAC-LDL to Daudi cells and lymphocytes
at 4°C
Incubating Daudi cells which were previously kept during 48 h in
medium containing 10% FCS with 3H-NOAC-LDL (10 nM LDL)
for 2 h at 4°C resulted in a fivefold increased binding compared to
lymphocytes (Figure 2A, left bars) reflecting the higher number of
LDL-receptors on Daudi cells. Pre-incubation of the cells with
250 nM LDL (1 h, 4°C) before addition of 3H-NOAC-LDL
blocked NOAC-LDL binding by 77 ± 6% to Daudi cells and by 52
± 14% to lymphocytes (Figure 2A, middle bars). Repeating the
same experiment with 250 nM empty control liposomes resulted in
the blocking of 88 ± 3% and 49 ± 8% of binding to Daudi cells or
lymphocytes respectively (Figure 2A, right bars). Similar results
were obtained for incubations with DiI-LDL. DiI-LDL binding to
Daudi cells was threefold higher than to lymphocytes. The binding
of DiI-LDL to Daudi cells was reduced to 14% after pre-incuba-
tion with a 25-fold excess of control LDL and to 29% after incuba-
tion with excess control liposomes (data not shown).
LDL-mediated uptake of NOAC in Daudi cells 1545
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Figure 2 Effects of culture conditions on the binding of NOAC-LDL to Daudi cells or lymphocytes. The cells were cultured for 48 h in medium with 10% FCS
(A: native receptors), 10% LPDS (B: up-regulated receptors) or 10% FCS plus 440 nM human LDL (C: down-regulated receptors) before incubation with NOAC-
LDL (10 nM NOAC) for 2 h at 4°C with (LDL, liposomes) or without (saline–EDTA) competitors, which were added 1 h before NOAC-LDL. Binding is shown as %
of total drug added
Table 1 Binding and uptake of 3H-NOAC incorporated in LDL or liposomes to Daudi cells or lymphocytes at 37°C
Pre-incubation for 1 h Buffer LDL Liposomes
Co-incubation for 2 h Buffer Colchicine Buffer Colchicine Buffer Colchicine
Binding and uptake (%)
3H-NOAC-LDL
Daudi cells 32.3 ± 1.0 (100%) 20.6 ± 1.6 (64%) 15.7 ± 0.1 (49%) 9.9 ± 0.9 (31%) 0.9 ± 0.08 (3%) ND
Lymphocytes 4.8 ± 0.4 (100%) ND 1.6 ± 0.1 (33%) ND 0.5 ± 0.1 (10%) ND
3H-NOAC-liposomes
Daudi cells 6.0 ± 0.3 (100%) 4.8 ± 0.2 (80%) 9.5 ± 0.1 (158%) ND 0.6 ± 0.03 (10%) 0.6 ± 0.05 (10%)
Lymphocytes 0.6 ± 0.1 (100%) ND 1.6 ± 0.1 (267%) ND 0.2 ± 0.03 (33%) ND
Results are means ± s.d. of three experiments; ND, not determined. Binding and uptake was calculated as % of total drug added. The corresponding effects of
the different incubation conditions were calculated by taking the standard buffer incubations as 100% (values shown in brackets).1546 SKM Koller-Lucae et al
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Culture of the cells for 48 h in medium containing 10% LPDS
instead of FCS resulted in a fivefold increased binding of
3H-NOAC-LDL to lymphocytes and only an insignificant receptor
up-regulation on Daudi cells (Figure 2B, left bars). About the same
amount of 3H-NOAC-LDL binding to up-regulated receptors was
blocked with excess control LDL, namely 69 ± 3% on Daudi cells
and 74 ± 4% on lymphocytes respectively (Figure 2B, right bars).
The up-regulation of LDL-receptors on Daudi cells cultured in
Table 2 Uptake and cellular distribution of NOAC incorporated in LDL or liposomes after 3 h incubation at 37°C
3H-NOAC-LDL 3H-NOAC-liposomes
Total uptake (pmol/106 Daudi cells) 105.7 ± 1.7 1753.2 ± 64.6
(% of total dpm added) 54.5 ± 0.9 10.1 ±0.4
(% of dpm in cells)
Nuclei/membranes 13.3 ± 1.8 5.5 ± 0.5
Mitochondria 37.2 ± 6.5 39.9 ± 6.0
Lysosomes 9.6 ± 0.6 10.7 ± 1.6
Microsomes 5.4 ± 0.1 5.9 ± 0.3
Cytosol 1.8 ± 0.2 3.0 ± 1.3
Recovery 67.2 ± 5.9 65.0 ± 5.4
Results are mean ± s.d, n = 3.
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Figure 3 Cell viability after incubation with different NOAC concentrations incorporated in LDL particles (A) or liposomes (B) or dissolved in ethanol (C)
compared to the carriers applied without drug (dotted lines). NOAC and corresponding carrier concentrations are indicated on the x-axes. The effect of ara-C
dissolved in saline–EDTA is shown in panel D. Incubations were performed during 24 h at 37°C. The results are shown as % viability referred to equal numbers
of control cells cultured in incubation medium without FCSLDL-mediated uptake of NOAC in Daudi cells 1547
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medium containing LPDS was confirmed by flow cytometric
investigations using DiI-LDL where a 3-fold shift of the mean
intensity of fluorescence (MIF) was observed (data not shown).
Culture of the cells in medium containing 10% FCS and addi-
tional human LDL resulted in a 30% decrease of NOAC-LDL
binding to Daudi cells but in no reduction for binding to lympho-
cytes (Figure 2C, left bars). Blocking with excess control LDL
reduced the binding only by 60 ± 2% for Daudi cells, whereas for
lymphocytes NOAC-LDL binding was reduced by 51 ± 10%
(Figure 2C, right bars). The comparison of NOAC-LDL binding to
native receptors on lymphocytes (Figure 2A, filled bars) with
down-regulated receptors (Figure 2C, filled bars) resulted in the
same blocking efficiency of 50%.
Binding and internalization of NOAC-LDL and NOAC-
liposomes at 37°C
Incubations at 37°C resulted in increased binding and internaliza-
tion of 3H-NOAC-LDL and 3H-NOAC-liposomes which was 
6–7 times higher in Daudi cells and 3–4 times in lymphocytes as
compared to the incubations at 4°C. From the total uptake values
shown in Table 1 the corresponding effects of the different
incubation conditions were calculated by taking the standard incu-
bations as 100%. Blocking of the LDL receptors with a 25-fold
excess of LDL reduced the 3H-NOAC-LDL uptake by 49% for
Daudi cells and by 67% for lymphocytes. After blocking the inter-
nalization by fluid phase pinocytosis by co-incubation with
colchicine 64% of LDL-mediated NOAC uptake and 80% of lipo-
somal NOAC uptake remained. After blocking with the combina-
tion of empty control LDL and colchicine, 31% of
3H-NOAC-LDL were still taken up by Daudi cells (Table 1). This
result indicates that at least these 31% of 3H-NOAC might have
been taken up through the membranes by other mechanisms than
receptor-mediated internalization or pinocytosis. Pre-incubation of
the cells with 250 nM control liposomes reduced binding of 3H-
NOAC-LDL to 3% and of 3H-NOAC-liposomes to 10% to Daudi
cells and to 10% and 33% to lymphocytes respectively.
Interestingly, the incubation of 3H-NOAC-liposomes with excess
LDL increased the 3H-NOAC binding to Daudi cells by 158% and
to lymphocytes by 267%.
Cytotoxicity
Incubation of Daudi cells with NOAC in LDL for 24 h resulted in
a IC50 of 160 mM NOAC (Figure 3A). Performing the same experi-
ment with NOAC in liposomes (Figure 3B) or NOAC dissolved in
ethanol (Figure 3C) gave IC50 values of 40 mM and 150 mM NOAC
respectively. The comparison of these incubations with control
incubations of identical LDL, liposome or ethanol concentrations
without drug revealed a moderate activation of the cell prolifera-
tion by LDL, a strong activation by liposomes and no change after
incubation with up to 2% (v/v) of ethanol (dotted lines in Figure
3). Ara-C had no cytotoxic effect under these incubation condi-
tions (Figure 3D). Blocking of the LDL receptors with 0.4 mM
LDL 25 min before addition of NOAC-LDL (0.6 mM LDL) corre-
sponding to 100 mM NOAC reduced the cytotoxicity by 34% and
the blocking of the LDL receptors with a twofold higher LDL
concentration of 1.2 mM reduced NOAC cytotoxicity by 51% (data
not shown).
To investigate the effect of serum proteins present during the
cytotoxicity experiments, 5% FCS was added to the medium. The
activating effect of additional lipids and cholesterol provided by
liposomes or LDL was less pronounced in the presence of serum
proteins. The NOAC-LDL mediated cytotoxicity was not influ-
enced by serum proteins, whereas the cytotoxicity of NOAC-lipo-
somes decreased by a factor of 2 and for NOAC dissolved in
ethanol it increased by a factor 2 at a NOAC concentration of
50 mM. According to serum-free incubations, ara-C cytotoxicity
was not observed in the presence of FCS.
Cellular distribution of 3H-NOAC-LDL or 3H-NOAC-
liposomes
The incubation of Daudi cells for 3 h with 0.07 mM 3H-NOAC-
LDL (30 molecules NOAC per LDL particle) or with 3 mM
3H-NOAC-liposomes (70 molecules NOAC per liposome) left
55% of 3H-NOAC-LDL and 10% of the liposomal formulation
associated with the cell pellet. Data of cellular drug distribution
are presented in Table 2.
The only difference was found in the membrane and nuclei frac-
tion where 13% of the 3H-NOAC-LDL and 6% 3H-NOAC-lipo-
somes were found. Highest drug concentrations were found in the
mitochondrial fraction for both applications.
DISCUSSION
In this study we compared cellular uptake and cytotoxicity in
Daudi cells of NOAC-LDL to liposomal NOAC. The incorpora-
tion of anticancer therapeutics into isolated LDL or LDL-frag-
ments for tumour targeting was investigated by several groups.
Rensen et al (1997) prepared LDL-like particles by using lipo-
somes which were modified with human recombinant apolipopro-
tein E. They found a LDL receptor-mediated uptake for these
modified liposomes to B16 melanoma cells, demonstrating that
these liposomes could be used to carry antineoplastic drugs to
tumours. Vitols et al (1990) incorporated a water-insoluble alkyl-
ating agent into LDL by incubating lyophilized LDL with the drug
solubilized in heptane followed by solvent evaporation before
adding buffer to the LDL–drug complex. Such elaborate in vitro
preparations are not necessary for NOAC because earlier investi-
gations revealed that NOAC is spontaneously transferred from
liposomes to LDL in human blood (Koller-Lucae et al, 1997).
The binding properties of LDL to the LDL receptor were not
impaired after incorporation of NOAC because comparable asso-
ciation constants were found for NOAC-LDL and DiI-LDL. This
is consistent with findings for other lipophilic compounds like
indium complexed to DTPA-stearylamide, which did not hinder
LDL-specific interactions with cells after incorporation into the
lipophilic part of the LDL particles (Jasanada et al, 1996). Yen and
co-workers (1995) reported that LDL receptors on Daudi cells
were already up-regulated which was reflected by elevated mRNA
for LDL receptors and insignificant increase of receptor density
after incubation in lipoprotein-deficient medium. Under normal
culture conditions LDL receptor expression on lymphocytes was
low which resulted in receptor up-regulation in lipoprotein-
deficient medium but in no down-regulation in the presence of
additional LDL in the culture medium. These results that are valid
for LDL interactions with lymphoma cells and lymphocytes were
confirmed in this study for 3H-NOAC incorporated into LDL
(Figure 3 A–C). Therefore we conclude that NOAC incorporated
into LDL can be taken up by the LDL receptor-mediated route.
The LDL receptor-mediated uptake of NOAC was also observed1548 SKM Koller-Lucae et al
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when liposomal NOAC was co-incubated with control LDL. This
route of uptake was probably followed by transfer of NOAC mole-
cules from the liposomes to LDL (Table 1).
In addition to specific binding, NOAC-LDL interacted also
unspecifically with cells because at 4°C only 77% of the binding
could be blocked with excess empty LDL. Goldstein and Brown
(1977) found that about 75% of LDL uptake by cells is LDL
receptor-mediated and they also observed LDL internalization on
fibroblasts by receptor-independent endocytosis. For the LDL-
associated cholesterol esters a receptor-independent uptake has
been described. After release from LDL these esters interact with
plasma membranes and are taken up by cells through an unspecific
mechanism (Rinninger et al, 1995). Thus, the co-transfer of
cholesterol esters and NOAC from LDL directly into cell
membranes could represent another possible mode of uptake for
NOAC. This hypothesis is supported by our finding that 31% of
NOAC binding and uptake has remained even after blocking
receptor-mediated LDL-uptake with excess LDL and co-incuba-
tion with colchicine to block unspecific pinocytosis. Accordingly,
Vitols et al (1990) described a LDL receptor-independent effect
resulting in the cytotoxic activity of a lipophilic mitoclomine-
derivative–LDL complex in mutated CHO cells which were
deprived of LDL receptors. This is in agreement with our results of
the cytotoxicity studies where 50% of the toxic effect of NOAC-
LDL remained after blocking the LDL receptors with empty
control LDL. Nevertheless, the cytotoxic effect of liposomal
NOAC was more pronounced than with NOAC-LDL, resulting in
IC50 values of 40mMand 160mMrespectively. NOAC-LDL was
shown to bind specifically with a much higher affinity to Daudi
cells than liposomal NOAC (Figure 1, Table 1). However, it has to
be taken into account that binding and uptake studies were
performed with NOAC-LDL and liposomal NOAC where each
carrier contained equal amounts of the drug, whereas for the cyto-
toxicity experiments liposomes carried about 40 times more
NOAC than the LDL particles (Figure 3). This means, that even
though liposomes bind less efficiently to Daudi cells they take up
40 times more drug with one liposome compared to one LDL
particle. Therefore the cytotoxic dose is reached earlier in cells
which are incubated with liposomal NOAC. The difference in
NOAC accumulation in cells when the carriers are loaded with
different amounts of drug is also presented in Table 2 for the
different drug carriers used. Additional lipids and cholesterol
administered as liposomes or LDL resulted in increased cell prolif-
eration and a viability of more than 100% compared to cells
cultured in serum-free medium (Figure 3A, B). The activating
effect of additional lipids and cholesterol provided by liposomes or
LDL was less pronounced in the presence of serum proteins. The
increased toxicity of NOAC dissolved in ethanol in incubations
with additional FCS was probably due to stabilization of NOAC in
the aqueous incubation medium by serum proteins, preventing
crystallization of excess drug. The decreased cytotoxicity of lipo-
somal NOAC under the same conditions may be caused by inter-
fering plasma proteins which bind to the liposomal surface to
prevent interaction with cells (Juliano, 1988). Ara-C was not toxic
to Daudi cells in incubations with or without FCS. This was
already described by Abe and his group (1982), who observed ara-
C toxicity only after 7 days of drug incubation. Vogler and
colleagues (1991) reported for different cytotoxic alkyl lysophos-
pholipids IC50 values determined in Daudi cells which were
comparable to our findings for NOAC.
In summary, the uptake experiments with the Daudi cells which
have highly up-regulated LDL receptors, resulted in a more effi-
cient uptake of NOAC-LDL compared to NOAC-liposomes. The
NOAC-LDL particles are taken up by the receptor route because
binding and internalization as well as toxicity can partially be
blocked with excess empty LDL. However, total blocking was not
achieved, suggesting the involvement of other unspecific uptake
mechanisms. NOAC does not necessarily need to be transferred to
LDL in order to act as a cytotoxic drug, since liposomal NOAC
was also active (cf. Figure 3B). Liposomes have the advantage that
they can carry much more NOAC molecules than LDL. In addi-
tion, liposomal drug preparations are much easier to formulate for
clinical preparations. The new anticancer drug NOAC has several
properties that are different to the parent drug ara-C. This was
demonstrated by its anti-tumour activity in the Daudi lymphoma
cells in this study, by comparative pharmacokinetic studies and in
xenograft mouse models (Schwendener et al, 1995). The transfer
of NOAC from liposomes to serum LDL could result in increased
drug uptake in tumour cells that express elevated LDL receptor
numbers, and thus, lead to an improved anti-tumour effect as
compared to other drugs.
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